|
CFCF is pleased to announce that this E-Update is supported by Novartis Pharmaceuticals Corporation |
Join iWalk for Carcinoid to Support the carcinoid and neuroendocrine community! Without leaving your home, putting on your sneakers, or spending any money, you can make a difference. CFCF can receive up to $10,000 from Novartis Pharmaceuticals Corporation that will enable scientific research that in pursuit of a cure! Click here to start iWalk-ing! |
 Follow us on Twitter!
 Join us on Facebook!
Visit us on Navigating Cancer! |
Submitted 10/2010
CFCF is honored to present Survivor Stories. They reflect remarkable courage and determination. Thank you to our Survivors for sharing their courage and words of hope with other patients. Read our newest survivor stories:
|
|
Join Us for a Cure
Make a difference and get involved with CFCF! Unite, meet fellow members of the carcinoid community, and spread awareness at upcoming CFCF events! |
Give hope and a future to neuroendocrine tumor patients: donate to CFCF where 100% of all individual donations go to carcinoid and related neuroendocrine tumor research. CFCF is a 501(c)(3) organization-all contributions are tax-deductible. We want our donors to know that we are allocating their donations responsibly and wisely to achieve a carcinoid cure as quickly as possible.
To learn more, view CFCF's:
Audited Financial Statements
IRS From 990
|
|
We are proud to be a BBB accredited charity!
CFCF meets all 20 Wise Giving Alliance standards for charity accountability established by the Better Business Bureau. Click here to check out the CFCF Wise Giving Report. | |
|
|
|
|
|
RADIANT Trials Find Everolimus to Improve Progression-Free Survival for Advanced Pancreatic Neuroendocrine Tumors and Carcinoid Tumors
 Findings from international RADIANT Phase III trials on everolimus (Afinitor) were presented at the 35th European Society for Medical Oncology Congress in Milan, Italy last month.
Advanced Pancreatic Neuroendocrine Tumors
Investigators in the RADIANT-3 trial found that when added to the best supportive care, everolimus was associated with a 65% reduction in the risk of progression and a 6.4 month increase in median progression-free survival among advanced pancreatic neuroendocrine tumor patients. RAD-3 investigator Dr. James Yao of MD Anderson Cancer Center stated, " Because treatment options available to patients with pancreatic neuroendocrine tumors are so limited, and the data in terms of the size of the treatment effect is so clear, I do believe this research will have immediate clinical implications. Hopefully, these findings will ultimately lead to a definitive change in the standard of care for those patients with pancreatic neuroendocrine tumors."
Based on these results, Novartis has announced that it will seek worldwide regulatory approval for everolimus (Afinitor) to expand its use for pancreatic neuroendocrine tumors.
Click here to read a press release on these pancreatic neuroendocrine tumor treatment findings. Carcinoid Tumors
Investigators in the RADIANT-2 trial found that in combination with octreotide LAR, everolimus extended median progression-free survival in carcinoid cancer patients. Findings demonstrated that the combination of therapies provided a clinically meaningful extension in median time without tumor growth from 11.3 to 16.4 months compared to octreotide plus placebo. According RAD-2 investigator, Dr. Marianne Pavel, " This Phase III study is important because it shows that everolimus plus octreotide LAR may provide a viable new treatment approach for patients with [carcinoid], where there is a high unmet need." Click here to read a press release on these carcinoid cancer treatment findings.
|
|
Phase III Trial Confirms Sunitinib Improves Progression-Free Survival Among Pancreatic Neuroendocrine Tumor Patients
 A retrospective, independent central review confirmed the benefit of sunitinib (Sutent) in extending progression-free survival among pancreatic neuroendocrine tumor patients. This analysis the original of phase-III trial showed that the median progression-free survival was 11.1 months with sunitinib versus 5.5 months with placebo. This review of data was necessary because it was suggested that the results of the original trial were subject to bias. According to Dr. Juan Velle of the Christie Hospital in Manchester, " The results were based on investigator assessments and once the trial was stopped, some commentators suggested that the results could have been biased because sunitinib can have some very particular and obvious side effects, therefore investigators may have been able to tell who was taking the active drug rather than placebo. An independent review was necessary to determine if the results stood up, irrespective of any unintentional unblinding." Click here to read a press release on the independent review of the Phase II trial on sunitinib. Patients should discuss these results with their doctor. Please call us at 617-848-3977 or visit our Doctor Database for assistance in finding a doctor. |
|
Nancy Lindholm Blogs on Current Topics in Ethics, Advocacy, and Education
 CFCF Founder Nancy Lindholm comments on a number of topics relevant in the neuroendocrine tumor community. Nancy considers the ethics of clinical trials in withholding effective drugs and celebrates Canadian rare disease activists for achieving progress in convincing the government to treat rare disease and orphan drugs differently. In her blog, Nancy also encourages the CFCF community to participate in the iWalk to support neuroendocrine tumor research and requests feedback and location suggestions for our 2011 Patient Education Conference series. Click here to read Nancy's newest blog. |
|
Lauren Erb Blogs on Raising Awareness for Worldwide NET Cancer Awareness Day
 In recognition of Worldwide NET Cancer Awareness Day, CFCF's Executive Director, Lauren Erb, shares what CFCF is doing to promote public awareness of neuroendocrine tumors.
In her latest blog, Lauren writes about Team CFCF's recent success in raising funds and awareness in the Chicago Marathon and Marine Corps Marathon and shares patient stories from her recent speech to the FDA regarding treatments for patients with rare diseases.
Lauren also invites YOU to join CFCF in spreading awareness for Worldwide NET Cancer Awareness Day on November 10, 2010. Click here to read Lauren's blog. |
|
Dr. Michael Zaruba Awarded "Young Physician of the Year" by Nebraska Medical Association
 Dr. Michael Zaruba was presented the "Young Physician of the Year Award" by the Nebraska Medical Association at its 142nd Annual Session. Dr. Zaruba was recognized for his medical contributions to the community and distinguished service to patients.
Dr. Zaruba serves as primary care doctor for Ruth Gerdes, a carcinoid survivor and national advocate for carcinoid patients, currently sitting on CFCF's Board of Patient Advisors. Ruth states, "It fills me with great joy how Dr. Zaruba has applied the knowledge he gained in researching my disease, and has so willingly helped other patients with carcinoid cancer."
Along with Ruth and a multidisciplinary team of physicians, Dr. Zaruba helped established the Carcinoid Clinic at the Nebraska Medical Center. The clinic offers quality and comprehensive care; patients meet doctors with a variety of specialties during their clinic visit. Dr. Zaruba is dedicated to taking carcinoid cancer from a medical curiosity to a curable condition.
To learn more about the Young Physician of the Year Award and about Dr. Zaruba's accomplishments, click here. |
|
Advertisement from our Sponsor
 |
|
|
|
|
